Want to see IONS full AI Analyst Report?

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

1,588 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IONS Analyst Ratings

Strong Buy

17 Buy

3 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Ionis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$94.11

▲(24.30% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $94.11 with a high forecast of $125.00 and a low forecast of $68.00. The average price target represents a 24.30% change from the last price of $75.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","60":"$60","82":"$82","104":"$104","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.11111111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$68.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,60,82,104,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.19,82.71384615384615,86.2376923076923,89.76153846153846,93.28538461538461,96.80923076923077,100.33307692307692,103.85692307692307,107.38076923076923,110.90461538461538,114.42846153846153,117.9523076923077,121.47615384615384,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.19,80.33777777777777,81.48555555555555,82.63333333333333,83.78111111111112,84.92888888888889,86.07666666666667,87.22444444444444,88.37222222222222,89.52,90.66777777777779,91.81555555555556,92.96333333333334,{"y":94.11111111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.19,78.32923076923076,77.46846153846154,76.6076923076923,75.74692307692308,74.88615384615385,74.02538461538461,73.16461538461539,72.30384615384615,71.44307692307692,70.5823076923077,69.72153846153846,68.86076923076924,{"y":68,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.11,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.96,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.28,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.38,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.19,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$125.00

Average Price Target$94.11

Lowest Price Target$68.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Akash Tewari

Jefferies

$90

Buy

18.87%

Upside

Reiterated

07/15/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

07/15/26

Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe ResearchIonis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research

Mitchell Kapoor

H.C. Wainwright

$125

Buy

65.10%

Upside

Reiterated

07/14/26

H.C. Wainwright trims Ionis price target, says trial failure reaction 'overdone'H.C. Wainwright trims Ionis price target, says trial failure reaction 'overdone'

Jessica Fye

J.P. Morgan

$72

Buy

-4.90%

Downside

Reiterated

07/14/26

J.P. Morgan Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

Luca Issi

RBC Capital

$100→$85

Buy

12.27%

Upside

Reiterated

07/13/26

Ionis Pharmaceuticals price target lowered to $85 from $100 at RBC CapitalIonis Pharmaceuticals price target lowered to $85 from $100 at RBC Capital

Yaron Werber

TD Cowen

$94

Buy

24.16%

Upside

Reiterated

07/10/26

Werber Maintains Buy on Wainua Maker, Cuts Target to $94 but Sees Pipeline Strength and Entry Opportunity After Trial Setback

Yanan Zhu

Wells Fargo

$100

Buy

32.08%

Upside

Assigned

07/10/26

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Eric Joseph

Citi

$115→$100

Buy

32.08%

Upside

Reiterated

07/10/26

Eric Joseph Lifts Ionis Price Target to $100, Reaffirming Buy Amid Adjusted Pipeline and Royalty Assumptions

Eliana Merle

Barclays

$115→$90

Buy

18.87%

Upside

Reiterated

07/10/26

Barclays Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Michael Ulz

Morgan Stanley

$130→$110

Buy

45.29%

Upside

Reiterated

07/10/26

Ionis Pharmaceuticals price target lowered to $110 from $130 at Morgan StanleyIonis Pharmaceuticals price target lowered to $110 from $130 at Morgan Stanley

Gary Nachman

Canaccord Genuity

$110→$95

Buy

25.48%

Upside

Reiterated

07/10/26

Canaccord Genuity Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Myles Minter

William Blair

―

Buy

―

Reiterated

07/09/26

Analyst Maintains Buy on Ionis, Viewing CARDIO-TTRansform Miss as Design-Driven and Highlighting 2026 ESC Data as Key Catalyst

Jason Gerberry

Bank of America Securities

$111→$90

Buy

18.87%

Upside

Reiterated

07/09/26

Ionis Pharmaceuticals price target lowered to $90 from $111 at BofAIonis Pharmaceuticals price target lowered to $90 from $111 at BofA

Joseph Stringer

Needham

$105→$86

Buy

13.59%

Upside

Assigned

07/09/26

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Ionis Pharmaceuticals (IONS)

Salveen Richter

Goldman Sachs

$75→$68

Hold

-10.18%

Downside

Reiterated

07/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and Guardant Health (NASDAQ: GH)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Akash Tewari

Jefferies

$90

Buy

18.87%

Upside

Reiterated

07/15/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

07/15/26

Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe ResearchIonis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research

Mitchell Kapoor

H.C. Wainwright

$125

Buy

65.10%

Upside

Reiterated

07/14/26

H.C. Wainwright trims Ionis price target, says trial failure reaction 'overdone'H.C. Wainwright trims Ionis price target, says trial failure reaction 'overdone'

Jessica Fye

J.P. Morgan

$72

Buy

-4.90%

Downside

Reiterated

07/14/26

J.P. Morgan Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

Luca Issi

RBC Capital

$100→$85

Buy

12.27%

Upside

Reiterated

07/13/26

Ionis Pharmaceuticals price target lowered to $85 from $100 at RBC CapitalIonis Pharmaceuticals price target lowered to $85 from $100 at RBC Capital

Yaron Werber

TD Cowen

$94

Buy

24.16%

Upside

Reiterated

07/10/26

Werber Maintains Buy on Wainua Maker, Cuts Target to $94 but Sees Pipeline Strength and Entry Opportunity After Trial Setback

Yanan Zhu

Wells Fargo

$100

Buy

32.08%

Upside

Assigned

07/10/26

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Eric Joseph

Citi

$115→$100

Buy

32.08%

Upside

Reiterated

07/10/26

Eric Joseph Lifts Ionis Price Target to $100, Reaffirming Buy Amid Adjusted Pipeline and Royalty Assumptions

Eliana Merle

Barclays

$115→$90

Buy

18.87%

Upside

Reiterated

07/10/26

Barclays Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Michael Ulz

Morgan Stanley

$130→$110

Buy

45.29%

Upside

Reiterated

07/10/26

Ionis Pharmaceuticals price target lowered to $110 from $130 at Morgan StanleyIonis Pharmaceuticals price target lowered to $110 from $130 at Morgan Stanley

Gary Nachman

Canaccord Genuity

$110→$95

Buy

25.48%

Upside

Reiterated

07/10/26

Canaccord Genuity Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Myles Minter

William Blair

―

Buy

―

Reiterated

07/09/26

Analyst Maintains Buy on Ionis, Viewing CARDIO-TTRansform Miss as Design-Driven and Highlighting 2026 ESC Data as Key Catalyst

Jason Gerberry

Bank of America Securities

$111→$90

Buy

18.87%

Upside

Reiterated

07/09/26

Ionis Pharmaceuticals price target lowered to $90 from $111 at BofAIonis Pharmaceuticals price target lowered to $90 from $111 at BofA

Joseph Stringer

Needham

$105→$86

Buy

13.59%

Upside

Assigned

07/09/26

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Ionis Pharmaceuticals (IONS)

Salveen Richter

Goldman Sachs

$75→$68

Hold

-10.18%

Downside

Reiterated

07/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and Guardant Health (NASDAQ: GH)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ENOVEnovis

GKOSGlaukos

IMUXImmunic

AVTXAvalo Therapeutics

TARAProtara Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

3 Months

Myles MinterWilliam Blair

Success Rate

12/20 ratings generated profit

Average Return

+11.65%

Copying Myles Minter's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +11.65% per trade.

1 Year

Gary NachmanCanaccord Genuity

Success Rate

16/25 ratings generated profit

Average Return

+24.99%

Copying Gary Nachman's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +24.99% per trade.

2 Years

Yanan ZhuWells Fargo

Success Rate

22/27 ratings generated profit

Average Return

+37.01%

Copying Yanan Zhu's trades and holding each position for 2 Years would result in 81.48% of your transactions generating a profit, with an average return of +37.01% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IONS has received 44 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. IONS average Analyst price target in the past 3 months is 94.11.

Each month's total comprises the sum of three months' worth of ratings.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$1.10 with a range of -$1.26 to -$0.84. The previous quarter’s EPS was -$0.56. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $187.14M with a range of $162.90M to $208.11M. The previous quarter’s sales results were $246.09M. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Stock Forecast FAQ

What is IONS’s average 12-month price target, according to analysts?

Based on analyst ratings, Ionis Pharmaceuticals Inc.’s 12-month average price target is 94.11.

What is IONS’s upside potential, based on the analysts’ average price target?

Ionis Pharmaceuticals Inc. has 24.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IONS a Buy, Sell or Hold?

Ionis Pharmaceuticals Inc. has a consensus rating of Strong Buy which is based on 17 buy ratings, 3 hold ratings and 0 sell ratings.

What is Ionis Pharmaceuticals Inc.’s price target?

The average price target for Ionis Pharmaceuticals Inc. is 94.11. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $125.00 ,the lowest forecast is $68.00. The average price target represents 24.30% Increase from the current price of $75.71.

What do analysts say about Ionis Pharmaceuticals Inc.?

Ionis Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of IONS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

IONS Analyst Ratings

IONS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ionis Pharmaceuticals

IONS Analyst Recommendation Trends

IONS Financial Forecast

IONS Earnings Forecast

IONS Sales Forecast

IONS Stock Forecast FAQ

Detailed List of Analyst Forecasts